anti 4-1BB/anti-B7-H3 bispecific antibody (Hefei Hanke Maibo Biotechnology)

N/A

Report date: 2025/06/11 10:21:17

Base Information

Drug Nameanti 4-1BB/anti-B7-H3 bispecific antibody (Hefei Hanke Maibo Biotechnology)

Drug Alias Namedual 4-1BB costimulator/anti-B7-H3 antibody (Hefei Hanke Maibo Biotechnology)HK-056-001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCD276 antigen modulatorsImmunostimulantsT lymphocytes stimulants +[4]

TargetsTumor necrosis factor receptor superfamily member 9CD276 antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesHefei Hankemab Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHefei Hankemab Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A